Lineage Cell Therapeutics secures $12 million from William Demant Invest for ReSonance™ (ANP1) development in hearing loss treatment.
Round Type
Funding Round
CarlsbadManufacturingBiotechnologyTherapeuticsInvestors
Description
Lineage Cell Therapeutics has entered a multi-year research collaboration with William Demant Invest to advance ReSonance (ANP1) for treating hearing loss. The investment will support preclinical development activities valued at up to $12 million. Development activities will be conducted jointly by Lineage and Eriksholm Research Centre scientists. This marks a significant step for Lineage's auditory neuronal cell transplant program.
Quick answer
Lineage Cell Therapeutics raised an undisclosed amount in a Funding Round round, dated August 26, 2025. Investors: William Demant Invest A/S. Lineage Cell Therapeutics is based in Carlsbad, California, United States.
- How much did Lineage Cell Therapeutics raise?
- Lineage Cell Therapeutics raised an undisclosed amount in a Funding Round round on August 26, 2025.
- Who invested in Lineage Cell Therapeutics?
- William Demant Invest A/S is named as investors in this round.
- What does Lineage Cell Therapeutics do?
- Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or 'off-the-shelf,' cell therapies to address unmet medical needs.
- Where is Lineage Cell Therapeutics based and how big is it?
- Lineage Cell Therapeutics is based in Carlsbad, California, United States. Fundz records about 70 employees.
- Who are the decision-makers at Lineage Cell Therapeutics?
- Fundz holds 5 contacts at Lineage Cell Therapeutics, including the Founder and CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Manufacturing around the same time
Companies in the same sectors as Lineage Cell Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- ENDRA Life Sciences raised $14M on October 10, 2025.
- ISOThrive raised $8.1M on October 10, 2025.
- Asterix Foods raised $4.2M (Seed) on October 8, 2025.
- Neuronoff raised $4.5M (Funding Round) on October 8, 2025.
- Arthrosi Therapeutics raised $153M (Series E) on October 8, 2025.
- ImmunoVec raised $41M (Grant) on October 8, 2025.
Who to call at Lineage Cell Therapeutics, and when
A new round usually means Lineage Cell Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Lineage Cell Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Lineage Cell Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Lineage Cell Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Lineage Cell Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Lineage Cell Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.